Marasmus Medication

  • Author: Simon S Rabinowitz, MD, PhD, FAAP; Chief Editor: Jatinder Bhatia, MBBS   more...
 
Updated: Mar 22, 2012
 

Medication Summary

No practical guidelines have been established for the most frequently used medications in marasmus. However, significant changes occur in their pharmacokinetics, resulting in unpredictable responses to drug therapy. Therefore, dosage adaptations are often necessary, and only the best-known medications and the absolutely necessary medications should be used.

Drug metabolism during marasmus

Absorption and bioavailability of oral drugs are decreased by the structural and functional changes of the digestive tract. Drug distribution depends on the fluid distribution, organ perfusion, and albumin level and is therefore significantly modified by marasmus. The hepatic metabolism is altered in marasmus; therefore, drugs metabolized in the liver must be used with caution. Renal elimination of drugs is also impaired with the changes in glomerular filtration and tubular secretion. Consequently, patients generally have a decrease of drug elimination, increase in plasmatic concentration, and increase in risk for toxicity. Drug metabolism perturbations improve rapidly with rehabilitation. Various pathophysiological changes that occur in protein energy malnutrition (PEM) and their effects on pharmacokinetic parameters are summarized in Table 4.

Table 4. Pathophysiology and its Relation to Pharmacokinetic Parameters in Malnourished Children (Open Table in a new window)

Physical ParameterPathophysiological ProfilePharmacokinetic Parameters
GI tract
  • Hypochlorhydria
  • Mucosal atrophy
  • Changes in transit time
  • Impaired pancreatic function
  • Altered gut microbial flora
  • Absorption
  • Enterohepatic circulation
  • Gut wall and gut bacterial metabolism
Body composition
  • Changes in protein/fat metabolism
  • Imbalance in body water distribution
  • Reduced sodium, potassium, and magnesium
  • Protein binding
  • Tissue uptake and distribution
  • Retention and elimination
Liver
  • Ultrastructural alterations
  • Decreased protein synthesis
  • Metabolism
  • Hepatic and biliary excretion
  • Enterohepatic circulation
Kidney
  • Reduced glomerular filtration
  • Impaired tubular function
  • Renal clearance
Cardiac system
  • Decreased cardiac output
  • Increased plasma volume
  • Organ blood flow
  • Tissue perfusion

Table 5. WHO Dosage Guidelines for Glucose (Dextrose if IV), Vitamins, and Minerals (Open Table in a new window)

Dextrose, Vitamins, and MineralsDosage
Glucose (dextrose)Conscious children: 50 mL 10% glucose or sucrose PO or 5 mL/kg of body weight of 10% dextrose IV, followed by 50 mL 10% glucose or sucrose by NG tube
Vitamin AInfants < 6 months: 50,000 IU/d PO for 2 d, followed by a third dose at least 2 wk later



Infants 6-12 months: 100,000 IU/d PO for 2 d, followed by a third dose at least 2 wk later



Children >12 months: 200,000 IU/d PO for 2 d, followed by a third dose at least 2 wk later



Folic acid5 mg PO on day 1, then 1 mg/d PO thereafter
MultivitaminsAll diets should be fortified with water-soluble and fat-soluble vitamins by adding, for example, the WHO vitamin mix (thiamine 0.7 mg/L, riboflavin 2 mg/L, nicotinic acid 10 mg/L, pyridoxine 0.7 mg/L, cyanocobalamin 1 mcg/L, folic acid 0.35 mg/L, ascorbic acid 100 mg/L, pantothenic acid 3 mg/L, biotin 0.1 mg/L, retinol 1.5 mg/L, calciferol 30 mcg/L, alpha-tocopherol 22 mg/L, vitamin K 40 mcg/L)
Iron supplementsProphylaxis: 1-2 mg elemental iron/kg/d PO; not to exceed 15 mg/d



Severe iron deficiency anemia: 4-6 mg elemental iron/kg/d PO divided tid



Mild-to-moderate iron deficiency anemia: 3 mg elemental iron/kg/d PO qd or divided bid



Precaution: GI irritation



Zinc sulfateSupplementation with ≥5 mg/d recommended for children aged 1 mo to 5 y with acute or persistent diarrhea (including dysentery)
Next

Antimicrobial agents

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting. Penicillin and aminoglycosides are eliminated by the kidney and have an increased plasma half-life. A decrease by 25% of the usual dosage is recommended with an increased period between doses from 12-24 hours for aminoglycosides and from 6-8 hours for penicillin. Chloramphenicol is still used in low-income countries and recommended in some WHO management protocols. It should be replaced by less toxic drugs (eg, ceftriaxone). Antituberculosis medications, such as isoniazid and rifampicin, are metabolized by the liver. To avoid serious liver failure, their dosage should be decreased by half and liver function should be monitored during treatment. Antimalarial drugs should be administrated according to local guidelines; except for quinine, they are not mentioned in this article.

View full drug information

Amoxicillin (Amoxil, Biomox, Polymox)

 

Aminopenicillin used for treatment of susceptible bacterial infections caused by streptococci, pneumococci, nonpenicillinase-producing staphylococci, Listeria species, meningococci, and some strains of Haemophilus influenzae, Salmonella species, Shigella species, Escherichia coli, and Enterobacter and Klebsiella species.

View full drug information

Ampicillin (Marcillin, Omnipen)

 

Aminopenicillin used for the treatment of susceptible bacterial infections caused by streptococci, pneumococci, nonpenicillinase-producing staphylococci, Listeria species, meningococci, and some strains of H influenzae, Salmonella species, Shigella species, E coli, and Enterobacter and Klebsiella species.

View full drug information

Ceftriaxone (Rocephin)

 

Cephalosporin (third generation) used for the treatment of serious infections due to susceptible organisms (eg, H influenzae, Enterobacteriaceae, N meningitidis, S pneumoniae).

View full drug information

Gentamicin

 

Aminoglycoside for gram-negative coverage. First-choice antibiotic associated with ampicillin for severe infection.

View full drug information

Nalidixic acid (NegGram)

 

Quinolone antibacterial for PO administration. It is a bactericidal agent, which appears to interfere with DNA polymerization by inhibition of DNA topoisomerase.

View full drug information

Penicillin G (Pfizerpen)

 

Natural penicillin used for the treatment of sepsis, meningitis, pericarditis, endocarditis, pneumonia, and other infections due to susceptible gram-positive organisms (except Staphylococcus aureus), some gram-negative organisms (Neisseria gonorrhoeae, N meningitidis) and some anaerobes and spirochetes.

View full drug information

Sulfamethoxazole and trimethoprim (Bactrim, Cotrim, Septra)

 

Synthetic antibacterial combination. Children with no apparent sign of infection should be administered cotrimoxazole as a first-choice antibiotic.

View full drug information

Isoniazid (Laniazid, Nydrazid)

 

Used for specific treatment of tuberculosis either alone for preventive therapy in patients who have a skin test conversion or in combination with other drugs for treatment of all active forms of the disease.

View full drug information

Rifampin (Rifadin, Rimactane)

 

Also called rifampicin. It is a synthetic derivative of a natural antibiotic rifamycin B. It is used in combination with other antitubercular drugs for the treatment of active tuberculosis. It also has antibacterial activity (eg, S aureus, Streptococcus pyogenes, N gonorrhoeae, H influenzae).

View full drug information

Quinine (Formula Q)

 

First antimalarial drug used for the treatment of chloroquine-resistant Plasmodium falciparum malaria.

Previous
Next

Antiprotozoal agents

Class Summary

Protozoal infections occur throughout the world and are a major cause of morbidity and mortality in some regions. Immunocompromised patients are especially at risk.

View full drug information

Albendazole (Albenza)

 

PO-administered broad-spectrum anthelmintic with specific indications, including ascariasis, hookworm infections, trichuriasis, and strongyloidiasis.

View full drug information

Metronidazole (Flagyl, Noritate, Protostat)

 

First-line treatment for amoebiasis and giardiasis.

Piperazine (Vermizine)

 

Treatment of ascariasis and trichuriasis.

Previous
Next

Antipyretic and analgesic agents

Class Summary

These agents inhibit central synthesis and release of prostaglandins that mediate the effect of endogenous pyrogens in the hypothalamus; thus, they promote the return of the set-point temperature to normal. Acetaminophen (paracetamol) metabolism during malnutrition is well documented. Its half-life is increased with the impaired hepatic metabolism and renal excretion, requiring a dosage decrease.

View full drug information

Acetaminophen (Acephen, Tylenol, Feverall, Panadol)

 

First-choice antipyretic drug; it is also used for the treatment of mild to moderate pain and fever. Reduces fever by acting directly on hypothalamic heat-regulating centers, which increases dissipation of body-heat via vasodilation and sweating.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Simon S Rabinowitz, MD, PhD, FAAP  Professor of Clinical Pediatrics, Vice Chairman, Clinical Practice Development, Pediatric Gastroenterology, Hepatology, and Nutrition, State University of New York Downstate College of Medicine, The Children's Hospital at Downstate

Simon S Rabinowitz, MD, PhD, FAAP is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American College of Gastroenterology, American Gastroenterological Association, American Medical Association, New York Academy of Sciences, North American Society for Pediatric Gastroenterology and Nutrition, Phi Beta Kappa, and Sigma Xi

Disclosure: Abbott nutrition Honoraria Speaking and teaching

Coauthor(s)

Mario Gehri, MD  Consulting Staff, Department of Pediatrics, Hôpital De L'Enfance, Centre Hospitalier Universitaire Vaudois, Switzerland

Disclosure: Nothing to disclose.

Ermindo R Di Paolo, PhD  Pharmacist, Department of Pharmacy, University Hospital CHUV, Lausanne, Switzerland

Disclosure: Nothing to disclose.

Natalia M Wetterer, MD  Resident Physician, Department of Pediatrics, New York Medical College

Disclosure: Nothing to disclose.

Esther N Prince, MD  Pediatric Gastroenterology Fellow, State University of New York Downstate Medical Center

Disclosure: Nothing to disclose.

Specialty Editor Board

Maria Rebello Mascarenhas, MBBS  Associate Professor of Pediatrics, University of Pennsylvania School of Medicine; Section Chief of Nutrition, Division of Gastroenterology and Nutrition, Director, Nutrition Support Service, Children's Hospital of Philadelphia

Maria Rebello Mascarenhas, MBBS is a member of the following medical societies: American Gastroenterological Association, American Society for Parenteral and Enteral Nutrition, and North American Society for Pediatric Gastroenterology and Nutrition

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Jatinder Bhatia, MBBS  Professor of Pediatrics, Chief, Section of Neonatology, Department of Pediatrics, Medical College of Georgia

Jatinder Bhatia, MBBS is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American Dietetic Association, American Pediatric Society, American Society for Clinical Nutrition, American Society for Parenteral and Enteral Nutrition, Society for Pediatric Research, and Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Merrily P M Poth, MD  Professor, Department of Pediatrics and Neuroscience, Uniformed Services University of the Health Sciences

Merrily P M Poth, MD is a member of the following medical societies: American Academy of Pediatrics, Endocrine Society, and Pediatric Endocrine Society

Disclosure: Nothing to disclose.

Chief Editor

Jatinder Bhatia, MBBS  Professor of Pediatrics, Chief, Section of Neonatology, Department of Pediatrics, Medical College of Georgia

Jatinder Bhatia, MBBS is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American Dietetic Association, American Pediatric Society, American Society for Clinical Nutrition, American Society for Parenteral and Enteral Nutrition, Society for Pediatric Research, and Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the use of images and information from the United Nations Children's Fund (UNICEF).

References

  1. Scrimshaw NS, Viteri FE. INCAP studies of kwashiorkor and marasmus. Food Nutr Bull. Mar 2010;31(1):34-41. [Medline].

  2. Spoelstra MN, Mari A, Mendel M, Senga E, van Rheenen P, van Dijk TH, et al. Kwashiorkor and marasmus are both associated with impaired glucose clearance related to pancreatic ß-cell dysfunction. Metabolism. Mar 2 2012;[Medline].

  3. Pelletier DL, Frongillo EA Jr, Schroeder DG, Habicht JP. The effects of malnutrition on child mortality in developing countries. Bull World Health Org. 1995;73 (4):443-8. [Medline].

  4. Joosten KF, Hulst JM. Prevalence of malnutrition in pediatric hospital patients. Curr Opin Pediatr. Oct 2008;20(5):590-6. [Medline].

  5. Pawellek I, Dokoupil K, Koletzko B. Prevalence of malnutrition in paediatric hospital patients. Clin Nutr. Feb 2008;27(1):72-6. [Medline].

  6. Akuyam SA, Isah HS, Ogala WN. Serum lipid profile in malnourished nigerian children in zaria. Niger Postgrad Med J. September 2008;15 (3):192-6.

  7. Emery PW. Metabolic changes in malnutrition. Eye. October 2005;19 (10):1029-32. [Medline].

  8. [Best Evidence] Lazzerini M, Ronfani L. Oral zinc for treating diarrhoea in children. Cochrane Database Syst Rev. 2008;(3):CD005436. [Medline].

  9. Altinkaynak S, Selimoglu MA, Ertekin V, Kilicarslan B. Serum ghrelin levels in children with primary protein-energy malnutrition. Pediatr Int. Aug 2008;50(4):429-31. [Medline].

  10. Kilic M, Taskin E, Ustundag B, Aygun AD. The evaluation of serum leptin level and other hormonal parameters in children with severe malnutrition. Clin Biochem. May 2004;37(5):382-7. [Medline].

  11. Hendricks KM, Duggan C, Gallagher L, et al. Malnutrition in hospitalized pediatric patients. Current prevalence. Arch Pediatr Adolesc Med. Oct 1995;149(10):1118-22. [Medline].

  12. Cameron JW, Rosenthal A, Olson AD. Malnutrition in hospitalized children with congenital heart disease. Arch Pediatr Adolesc Med. Oct 1995;149(10):1098-102. [Medline].

  13. Fisberg M, Nobrega FJ. Disturbios da nutricao. Revinter. 1998;140-4.

  14. Manejo da desnutricao grave: um manual para profissionals de saude de nivel superior (medicos, enfermeiros, nutricionistas e outros) e suaas equipes auxillares. Organizacao Mundial da Saude, Brasilia. 1999.

  15. Rocha GA, Rocha EJ, Martins CV. The effects of hospitalization on the nutritional status of children. J Pediatr (Rio J). Jan-Feb 2006;82(1):70-4. [Medline].

  16. Marteletti O, Caldari D, Guimber D, Mention K, Michaud L, Gottrand F. [Malnutrition screening in hospitalized children: influence of the hospital unit on its management]. Arch Pediatr. Aug 2005;12(8):1226-31. [Medline].

  17. Oztürk Y, Buyukgebiz B, Arslan N, Ellidokuz H. Effects of hospital stay on nutritional anthropometric data in Turkish children. J Trop Pediatr. Jun 2003;49(3):189-90. [Medline].

  18. World Health Organization. WHO Global Database on Child Growth and Malnutrition. Geneva: WHO. 1996.

  19. Kim Y, Hahn S, Garner P. Reduced osmolarity oral rehydration solution for treating dehydration caused by acute diarrhoea in children. Cochrane Database Syst Rev. 2001;(2):CD002847. [Medline].

  20. UNICEF. New formulation of Oral Rehydration Salts (ORS) with reduced osmolarity. United Nations Children's Fund. Available at http://www.supply.unicef.dk/catalogue/bulletin9.htm.

  21. Plumpy'nut. Available at http://en.wikipedia.org/wiki/Plumpy'nut.

  22. Joint Statement by the World Health Organization, the World Food Programme, the United Nations System Standing Committee on Nutrition and the United Nations Children's Fund. Community-Based Management of Severe Acute Malnutrition. May, 2007.

  23. [Guideline] World Gastroenterology Organisation (WGO). WGO practice guideline: acute diarrhea. Mar 2008;[Full Text].

  24. Schwarz SM, Corredor J, Fisher-Medina J, Cohen J, Rabinowitz S. Diagnosis and treatment of feeding disorders in children with developmental disabilities. Pediatrics. Sep 2001;108(3):671-6. [Medline].

  25. Bhutta ZA, Ahmed T, Black RE, Cousens S, Dewey K, Giugliani E. What works? Interventions for maternal and child undernutrition and survival. Lancet. Feb 2 2008;371(9610):417-40. [Medline].

  26. Ashworth A, Jackson A, Khanum S, Schofield C. Ten steps to recovery. Child Health Dialogue. 1996;10-2. [Medline].

  27. Barennes H, Kahiatani F, Pussard E, et al. Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. Trans R Soc Trop Med Hyg. Jul-Aug 1995;89(4):418-21. [Medline].

  28. Beaufrere B, Bresson JL, Briend A, et al. Protein and energy requirements in children with severe malnutrition. Application in a hospital environment for the treatment of malnutrition caused by deficient intake. Arch Pediatr. 1998;5(7):763- 71. [Medline].

  29. Berkley J, Mwangi I, Griffiths K, et al. Assessment of severe malnutrition among hospitalized children in rural Kenya: comparison of weight for height and mid upper arm circumference. JAMA. Aug 3 2005;294(5):591-7. [Medline].

  30. Briend A, Wojtyniak B, Rowland MG. Arm circumference and other factors in children at high risk of death in rural Bangladesh. Lancet. Sep 26 1987;2(8561):725-8. [Medline].

  31. Buchanan N. Drug kinetics in protein energy malnutrition. S Afr Med J. Mar 4 1978;53(9):327-30. [Medline].

  32. Buchanan N. Effect of protein-energy malnutrition on drug metabolism in man. World Rev Nutr Diet. 1984;43:129-39. [Medline].

  33. Buchanan N, Eyberg C, Davis MD. Isoniazid pharmacokinetics in Kwashiorkor. S Afric Med J. 1979;56(8):299-300. [Medline].

  34. Buchanan N, Robinson R, Koornhof HJ, Eyberg C. Penicillin pharmacokinetics in kwashiorkor. Am J Clin Nutr. Nov 1979;32(11):2233-6. [Medline].

  35. El-Sayed HL, Nassar MF, Habib NM, et al. Structural and functional affection of the heart in protein energy malnutrition patients on admission and after nutritional recovery. Eur J Clin Nutr. Apr 2006;60(4):502-10. [Medline].

  36. Finch RG. Adverse reactions to antibiotics. In: Greenwood D, ed. Antimicrobial Chemotherapy. 4th ed. Oxford, England: Oxford University Press; 2000:200-11.

  37. Golden M. The effects of malnutrition in the metabolism of children. Trans R Soc Trop Med Hyg. 1988;82(1):3-6. [Medline].

  38. Gomez F, Ramos Galvan R, Frenk S, et al. Mortality in second and third degree malnutrition. In: Bull World Health Organ. 2000;78(10):1275-80. J Trop Ped and Afr Child Health. 1956;2:77. [Medline].

  39. Grantham-McGregor S. A review of studies of the effect of severe malnutrition on mental development. J Nutr. 1995;125:2233-8 S. [Medline].

  40. Krishnaswamy K. Drug metabolism and pharmacokinetics in malnourished children. Clin Pharmacokinet. 1989;17 Suppl 1:68-88. [Medline].

  41. Listernick R, Christoffel K, Pace J, Chiaramonte J. Severe primary malnutrition in US children. Am J Dis Child. Nov 1985;139(11):1157-60. [Medline].

  42. Long J, World Health Organization. Management of severe malnutrition: a manual for physicians and senior health workers. 1999.

  43. Martorell R, Habicht J-P, Rivera JA. History and design of the INCAP Longitudinal Study (1969-77) and its Follow-up (1988-89). J Nutr. 1995;125:1027-41 S. [Medline].

  44. Mazouni SM, Guignard JP. [Malnutrition in children and the variability of drug effects]. Rev Med Suisse Romande. Dec 1996;116(12):965-9. [Medline].

  45. Mehta S. Drug metabolism in the malnourished child. Nestle nutr workshop ser. 1988;19:329-38.

  46. Mehta S, Nain CK, Sharma B, Mathur VS. Disposition of four drugs in malnourished children. Drug Nutr Interact. 1982;1(3):205-11. [Medline].

  47. Mehta S, Nain CK, Yadav D, et al. Disposition of acetaminophen in children with protein calorie malnutrition. Int J Clin Pharmacol Ther Toxicol. Jun 1985;23(6):311-5. [Medline].

  48. Merritt RJ, Suskind RM. Nutritional survey of hospitalized pediatric patients. Am J Clin Nutr. Jun 1979;32(6):1320-5. [Medline].

  49. Polasa K, Murthy KJ, Krishnaswamy K. Rifampicin kinetics in undernutrition. Br J Clin Pharmacol. Apr 1984;17(4):481-4. [Medline].

  50. Pollitt E. Developmental sequel from early nutritional deficiencies: conclusive and probability judgments. J Nutr. Feb 2000;130(2S Suppl):350S-353S. [Medline].

  51. Rumack BH, Holtzman J, Chase HP. Hepatic drug metabolism and protein malnutrition. J Pharmacol Exp Ther. Sep 1973;186(3):441-6. [Medline].

  52. Seth V, Beotra A, Bagga A, Seth S. Drug therapy in malnutrition. Indian Pediatr. Nov 1992;29(11):1341-6. [Medline].

  53. Taketomo CK, Hodding JH, Kraus DM. Pediatric dosage handbook. 12th ed. Hudson, Ohio: Lexi Comp Inc; 2005.

  54. Tolboom JJ. Management of severe malnutrition and diarrhea. J Pediatr Gastroenterol Nutr. Mar 2000;30(3):346-8. [Medline].

  55. Waterlow JC. Classification and definition of protein-calorie malnutrition. Br Med J. Sep 2 1972;3(826):566-9. [Medline].

  56. Yadav D. Disposition of acetaminophen in children with protein caloric malnutrition. Clin Pharmacol Ther. 1985;23:311-5.

 
Previous
Next
 
Malnutrition hotspot map. Image courtesy of the World Health Organization (WHO) and United Nations Children's Fund (UNICEF).
Physiopathological principle of arm circumference measurement in children aged 1-5 years and the relationship with severity of malnutrition.
Hormonal adaptation to the stress of malnutrition. The evolution of marasmus.
Distribution of 10.4 million deaths among children younger than 5 years in all developing countries. World health Organization (WHO), 1995.
Clinical course of marasmus (history).
A classic example of a weight chart for a severely malnourished child.
General principles of severe malnutrition management. KW = Kwashiorkor.
Table 1. WHO Classification of Malnutrition
Evidence of MalnutritionModerateSevere (type)
Symmetric edemaNoYes (edema protein-energy malnutrition [PEM])*
Weight for height†Standard deviation (SD)‡ score -3



SD score <-2 (70-90%)§



SD score <-3 (ie, severe wasting) || (< 70%)
Height for ageSD score- 3



SD score <-2 (85-89%)



SD score <-3 (ie, severe stunting) (< 85%)
* This includes kwashiorkor (KW) and kwashiorkor marasmus (presence of edema always indicates serious PEM).



† Standing height should be measured in children taller than 85 cm, and supine length should be measured in children shorter than 85 cm or in children who are too sick to stand. Generally, the supine length is considered to be 0.5 cm longer than the standing height; therefore, 0.5 cm should be deducted from the supine length measured in children taller than 85 cm who are too sick to stand.



‡ Below the median National Center for Health Statistics (NCHS)/WHO reference: The SD score is defined as the deviation of the value for an individual from the median value of the reference population divided by the standard deviation of the reference population (ie, SD score = [observed value – median reference value]/standard deviation of reference population).



§ This is the percentage of the median NCHS/WHO reference.



|| This corresponds to marasmus (without edema) in the Wellcome clinical classification and to grade III malnutrition in the Gomez system. However, to avoid confusion, the term severe wasting is preferred.



Table 2. Composition Comparison of ReSoMal, Standard WHO, and Reduced-Osmolarity WHO ORS Solutions
CompositionReSoMal (mmol/L)Standard ORS (mmol/L)Reduced osmolarity ORS
Glucose12511175
Sodium459075
Potassium402020
Chloride708065
Citrate71010
Magnesium3......
Zinc0.3......
Copper0.045......
Osmolarity (mOsm/L)300311245
Table 3. Preparation of F75 and F100 Diets (WHO)
IngredientAmount in F75Amount in F100
Dry skimmed milk25 g80 g
Sugar70 g50 g
Cereal flour35 g...
Vegetable oil27 g60 g
Mineral mix20 mL20 mL
Vitamin mix140 mg140 mg
Water to mix1000 mL1000 mL
Table 4. Pathophysiology and its Relation to Pharmacokinetic Parameters in Malnourished Children
Physical ParameterPathophysiological ProfilePharmacokinetic Parameters
GI tract
  • Hypochlorhydria
  • Mucosal atrophy
  • Changes in transit time
  • Impaired pancreatic function
  • Altered gut microbial flora
  • Absorption
  • Enterohepatic circulation
  • Gut wall and gut bacterial metabolism
Body composition
  • Changes in protein/fat metabolism
  • Imbalance in body water distribution
  • Reduced sodium, potassium, and magnesium
  • Protein binding
  • Tissue uptake and distribution
  • Retention and elimination
Liver
  • Ultrastructural alterations
  • Decreased protein synthesis
  • Metabolism
  • Hepatic and biliary excretion
  • Enterohepatic circulation
Kidney
  • Reduced glomerular filtration
  • Impaired tubular function
  • Renal clearance
Cardiac system
  • Decreased cardiac output
  • Increased plasma volume
  • Organ blood flow
  • Tissue perfusion
Table 5. WHO Dosage Guidelines for Glucose (Dextrose if IV), Vitamins, and Minerals
Dextrose, Vitamins, and MineralsDosage
Glucose (dextrose)Conscious children: 50 mL 10% glucose or sucrose PO or 5 mL/kg of body weight of 10% dextrose IV, followed by 50 mL 10% glucose or sucrose by NG tube
Vitamin AInfants < 6 months: 50,000 IU/d PO for 2 d, followed by a third dose at least 2 wk later



Infants 6-12 months: 100,000 IU/d PO for 2 d, followed by a third dose at least 2 wk later



Children >12 months: 200,000 IU/d PO for 2 d, followed by a third dose at least 2 wk later



Folic acid5 mg PO on day 1, then 1 mg/d PO thereafter
MultivitaminsAll diets should be fortified with water-soluble and fat-soluble vitamins by adding, for example, the WHO vitamin mix (thiamine 0.7 mg/L, riboflavin 2 mg/L, nicotinic acid 10 mg/L, pyridoxine 0.7 mg/L, cyanocobalamin 1 mcg/L, folic acid 0.35 mg/L, ascorbic acid 100 mg/L, pantothenic acid 3 mg/L, biotin 0.1 mg/L, retinol 1.5 mg/L, calciferol 30 mcg/L, alpha-tocopherol 22 mg/L, vitamin K 40 mcg/L)
Iron supplementsProphylaxis: 1-2 mg elemental iron/kg/d PO; not to exceed 15 mg/d



Severe iron deficiency anemia: 4-6 mg elemental iron/kg/d PO divided tid



Mild-to-moderate iron deficiency anemia: 3 mg elemental iron/kg/d PO qd or divided bid



Precaution: GI irritation



Zinc sulfateSupplementation with ≥5 mg/d recommended for children aged 1 mo to 5 y with acute or persistent diarrhea (including dysentery)
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.